Pharmadrug Production

What Pharmadrug Production does

PharmaDrug Inc. is a Canadian-domiciled, publicly traded specialty pharmaceutical company (CSE: PHRX, OTCQB: LMLLF) that operates two pillars: Sairiyo Therapeutics, focused on clinical development of reformulated natural medicines, and SecureDose Synthetics, focused on bio-synthetic formulations of controlled substances. Its lead clinical asset is PD-001, a patented enteric-coated oral formulation of cepharanthine designed to solve the bioavailability limitations of generic cepharanthine; the FDA approved a Phase 1 clinical trial in August 2024. The pipeline also includes DMT analogues targeted at glaucoma and ischemia-reperfusion injury in organ transplant patients (both with FDA Orphan Drug Designations) and a patent-pending biosynthetic pharmaceutical-grade cocaine program under SecureDose.

The company generates revenue primarily through its wholly-owned German subsidiary, Pharmadrug Production GmbH, which holds a Schedule I EU narcotics license and German EuGMP certification and distributes medical cannabis products (Dronabinol, THC oils, cannabis flowers) to pharmacies in Germany and across the EU. Forward-looking revenue is expected from commercialization of PD-001 and DMT-based products in rare cancers, infectious diseases (COVID-19, hantavirus), glaucoma, and organ transplant indications, supplemented by licensing and royalty potential upon regulatory approval. Other subsidiaries include Super Smart, a Dutch adult-use psychedelic retail venture.

The company's customers today are German and EU pharmacies served via its distribution network; its future commercial customers are fragmented end-patient populations across multiple rare-disease and specialty indications. GTM motion is primarily channel-partner-driven distribution in Germany/EU combined with academic and contract research partnerships (Johns Hopkins, Terasaki Institute, Southwest Research Institute, University of Michigan) to advance clinical-stage assets. Pricing is not publicly disclosed, and PharmaDrug has not yet commercialized any of its drug development candidates, so the bulk of near-term revenue depends on the German medical cannabis distribution business.

Name

Pharmadrug Production

Legal name

PharmaDrug Inc.

Website

https://pharmadrug.ca

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

PharmaDrug Inc. is a clinical-stage specialty pharmaceutical company developing reformulated natural medicines (PD-001/cephalexin, DMT analogues) and biosynthetic controlled substances, while distributing medical cannabis to pharmacies in Germany and the EU through its Pharmadrug Production GmbH subsidiary.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

akta.pro secondary industry

Medical Cannabis Delivery & Online Ordering (CRANAGAG)

Keywords

• Pharmaceutical distribution
• Medical cannabis distribution
• EU GMP certified supply
• Narcotics licensed distribution
• Pharmacy wholesale supply

Headquarters

HQ city

Rostock

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Medical Cannabis Distribution: Distribution of medical cannabis products (Dronabinol, THC oils, cannabis flowers) to pharmacies in Germany and throughout the EU via Pharmadrug Production GmbH subsidiary, which holds Schedule I EU narcotics license and German EuGMP certification.
2. Pharmaceutical Drug Development & Licensing: Development of patented drug formulations (PD-001 for cepharanthine, DMT analogues) through clinical trials with potential for future licensing or commercialization upon regulatory approvals.
3. Drug Commercialization: Future revenue from commercialization of approved drug products for rare cancers and infectious diseases upon successful completion of clinical trials and FDA approvals.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Pharmadrug Production GmbH is a German pharmaceutical distribution company that imports and distributes EU-GMP-certified medical cannabis products, including Dronabinol, THC oils, and cannabis flowers, to licensed pharmacies across Germany and the European Union. It operates under a Schedule I EU narcotics license and German EuGMP certification, enabling compliant handling and supply of controlled pharmaceutical-grade cannabis products.

Product overview

Pharmadrug Inc. is a specialty pharmaceutical company structured as a platform with multiple divisions and subsidiaries. The company operates through two core pillars: Sairiyo Therapeutics (biotechnology) developing PD-001 (patented enteric-coated Cepharanthine) for cancer and infectious diseases, and SecureDose Synthetics (synthetic formulations) developing biosynthetic pharmaceutical products. The portfolio includes drug candidates PD-001 for esophageal cancer and COVID-19, DMT formulations for glaucoma and organ transplant indications, and biosynthetic cocaine. Subsidiaries include Pharmadrug Production GmbH (German medical cannabis distributor with EuGMP certification) and Super Smart (Dutch psychedelic retail business).

Differentiator

Problem solved

Functional benefit

Brands

• Sairiyo Therapeutics: Biotechnology division focused on clinical development of reformulated natural-based medicines including PD-001 (patented reformulated cepharanthine) for oncology and infectious diseases, and DMT research programs
• SecureDose
• SecureDose Synthetics
• Super Smart

Products and services

• Medical Cannabis Distribution (Dronabinol, THC Oils, Cannabis Flowers) Distribution of pharmaceutical-grade medical cannabis products including Dronabinol, THC oils, and cannabis flowers to licensed pharmacies in Germany and throughout the EU. The subsidiary holds Schedule I EU narcotics license and German EuGMP certification, enabling compliant importation and wholesale supply of controlled cannabis substances to pharmacy customers.

Quantifiable outcome

• Cepharanthine showed 99.96% growth inhibition at top concentration tested against esophageal cancer cells, approximately 5-times greater potency than cisplatin chemotherapy
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Canurta Inc.coreStrategic or Co-development Partner · 30 October 2025Definitive agreement to acquire equity interest in Canurta Inc., representing strategic investment in company's pipeline expansion. Initial 19.9% interest acquired in January 2026 with completion of debt restructuring.
• Canadian Controlled Drug Substance Licensed DealerminorChannel Partner/ Reseller/ Distributor · 23 May 2024SecureDose signed LOI with Canadian controlled drug substance licensed dealer for patent pending pharmaceutical-grade cocaine distribution.
• Southwest Research Institute (SwRI)coreTechnology or Integration · 26 January 2022Engaged for cGMP manufacturing activities of PD-001, the patented enteric-coated oral formulation of cepharanthine. SwRI has previous track record for producing the Company's drug substance and drug product according to required specifications for clinical studies.
• Johns Hopkins University (JHU)coreStrategic or Co-development Partner · 25 August 2021Clinical research collaboration with JHU Center for Psychedelic and Consciousness Research to conduct clinical study comparing acute and enduring psychological and neural effects of DMT and an undisclosed potently active comparator molecule. Principal investigator Dr. Frederick S. Barrett. Company has exclusive option to obtain worldwide, royalty-bearing commercialization license to all invention rights from the study.
• Terasaki Institute for Biomedical InnovationcoreStrategic or Co-development Partner · 5 August 2021Sponsored research agreement to develop novel ocular drug delivery platform to deliver DMT and other tryptamine-based pharmaceuticals for eye diseases including glaucoma. Studies include cell-based research, active pharmaceutical ingredient formulation, and novel delivery technologies. TIBI has expertise in biomaterials, cellular and tissue engineering, wearable biosensors and polymer development.
• PharmaTherminorStrategic or Co-development PartnerCollaboration with PharmaTher for development of DMT transdermal patch for potential neuropsychiatric applications.
• University of MichiganminorStrategic or Co-development PartnerResearch partnership to study the role of endogenous DMT in the brain, investigating how DMT impacts health and disease outside of psychotropic effects.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Canopy Growth: Major Canadian-based cannabis operator with European operations including a German subsidiary distributing medical cannabis to pharmacies. Comparable B2B medical cannabis distribution model, but serves a much broader product and geographic footprint.
• STADA Arzneimittel: Major German specialty and generic pharmaceutical manufacturer and distributor with broad EuGMP-certified operations across Europe. Comparable as a large incumbent in specialty pharma distribution against which PharmaDrug Production competes for pharmacy supply contracts.
• Aurora Cannabis: Canadian cannabis producer with established European medical cannabis distribution operations in Germany. Overlaps with PharmaDrug Production GmbH on EuGMP-certified wholesale to German pharmacies.
• Tilray Brands: Large publicly traded global cannabis company with established medical cannabis distribution across Germany, Portugal and other EU markets. Overlaps with PharmaDrug's pharmacy distribution channel at a much larger scale and broader product portfolio.

Emerging players

• GH Research: Clinical-stage psychedelic drug developer focused on mebufotenin (5-MeO-DMT) for depression and other psychiatric disorders. Comparable DMT-class drug development platform with overlapping indications and regulatory pathway experience.
• Beckley Psytech: Private psychedelic medicine company developing psilocybin and other psychedelic candidates through clinical trials. Comparable development-stage peer in reformulated psychedelic drug delivery, with overlapping partnership-oriented R&D model.
• Atai Life Sciences: Listed clinical-stage biotech building a pipeline of psychedelic and complementary therapies for mental health indications. Comparable in capital-markets profile and psychedelic drug development, but focuses on neuropsychiatric indications rather than PharmaDrug's oncology/glaucoma/transplant focus.

Direct peers

• Demecan: Vertically integrated German medical cannabis cultivator and distributor supplying pharmacies across Germany. Mirrors PharmaDrug Production GmbH's EuGMP-certified pharmacy channel strategy in the same German market.
• Sanity Group: Berlin-based medical cannabis and psychedelic therapy company with German cultivation and distribution operations. Highly comparable German/EU medical cannabis wholesale footprint, similar regulatory emphasis.
• PharmaTher: Specialty pharmaceutical company developing DMT (including a transdermal patch) for neurological and rare-disease indications. PharmaDrug has an active DMT transdermal-patch collaboration with PharmaTher, making it the closest direct competitor and collaborator in psychedelic drug reformulation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pharmadrug-international-gmbh

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmadrug Production